Terzikhan Natalie, Verhamme Katia M C, Hofman Albert, Stricker Bruno H, Brusselle Guy G, Lahousse Lies
Department of Respiratory Medicine, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium.
Department of Epidemiology, Erasmus Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
Eur J Epidemiol. 2016 Aug;31(8):785-92. doi: 10.1007/s10654-016-0132-z. Epub 2016 Mar 5.
COPD is the third leading cause of death in the world and its global burden is predicted to increase further. Even though the prevalence of COPD is well studied, only few studies examined the incidence of COPD in a prospective and standardized manner. In a prospective population-based cohort study (Rotterdam Study) enrolling subjects aged ≥45, COPD was diagnosed based on a pre-bronchodilator obstructive spirometry (FEV1/FVC < 0.70). In absence of an interpretable spirometry within the Rotterdam Study, cases were defined as having COPD diagnosed by a physician on the basis of clinical presentation and obstructive lung function measured by the general practitioner or respiratory physician. Incidence rates were calculated by dividing the number of incident cases by the total number of person years of subjects at risk. In this cohort of 14,619 participants, 1993 subjects with COPD were identified of whom 689 as prevalent ones and 1304 cases as incident ones. The overall incidence rate (IR) of COPD was 8.9/1000 person-years (PY); 95 % Confidence Interval (CI) 8.4-9.4. The IR was higher in males and in smokers. The proportion of female COPD participants without a history of smoking was 27.2 %, while this proportion was 7.3 % in males. The prevalence of COPD in the Rotterdam Study is 4.7 % and the overall incidence is approximately 9/1000 PY, with a higher incidence in males and in smokers. The proportion of never-smokers among female COPD cases is substantial.
慢性阻塞性肺疾病(COPD)是全球第三大死因,预计其全球负担还会进一步增加。尽管对COPD的患病率已有充分研究,但仅有少数研究以前瞻性和标准化的方式调查了COPD的发病率。在一项纳入年龄≥45岁受试者的基于人群的前瞻性队列研究(鹿特丹研究)中,根据支气管扩张剂使用前的阻塞性肺功能测定(FEV1/FVC < 0.70)诊断COPD。在鹿特丹研究中,若无法进行可解读的肺功能测定,则将病例定义为根据临床表现被医生诊断为COPD且由全科医生或呼吸科医生测量有阻塞性肺功能的患者。发病率通过将新发病例数除以处于危险中的受试者的总人年数来计算。在这个由14619名参与者组成的队列中,确定了1993例COPD患者,其中689例为现患病例,1304例为新发病例。COPD的总体发病率(IR)为8.9/1000人年(PY);95%置信区间(CI)为8.4 - 9.4。男性和吸烟者的发病率更高。无吸烟史的女性COPD参与者比例为27.2%,而男性这一比例为7.3%。鹿特丹研究中COPD的患病率为4.7%,总体发病率约为9/1000 PY,男性和吸烟者的发病率更高。女性COPD病例中从不吸烟者的比例相当大。